DK200201741A - Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum - Google Patents
Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum Download PDFInfo
- Publication number
- DK200201741A DK200201741A DK200201741A DKPA200201741A DK200201741A DK 200201741 A DK200201741 A DK 200201741A DK 200201741 A DK200201741 A DK 200201741A DK PA200201741 A DKPA200201741 A DK PA200201741A DK 200201741 A DK200201741 A DK 200201741A
- Authority
- DK
- Denmark
- Prior art keywords
- plasmodium
- protein
- merozoite surface
- falcinarum
- surface protein
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 title abstract description 9
- 229960005486 vaccine Drugs 0.000 title abstract description 9
- 241000223960 Plasmodium falciparum Species 0.000 title abstract description 7
- 102000018697 Membrane Proteins Human genes 0.000 title abstract description 4
- 108010052285 Membrane Proteins Proteins 0.000 title abstract description 4
- 201000004792 malaria Diseases 0.000 title abstract description 4
- 210000003936 merozoite Anatomy 0.000 title abstract description 4
- 241000224016 Plasmodium Species 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 3
- 229930195712 glutamate Natural products 0.000 abstract description 3
- 230000005875 antibody response Effects 0.000 abstract 2
- 241000194035 Lactococcus lactis Species 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 235000014897 Streptococcus lactis Nutrition 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020001775 protein parts Proteins 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 101100024442 Anaplasma marginale msp4 gene Proteins 0.000 description 1
- 101100373500 Enterobacteria phage T4 y06N gene Proteins 0.000 description 1
- 101100373502 Enterobacteria phage T4 y06P gene Proteins 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 102000004866 Microtubule-associated protein 1B Human genes 0.000 description 1
- 108090001040 Microtubule-associated protein 1B Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101000967612 Onchocerca volvulus Major sperm protein 2 Proteins 0.000 description 1
- 101000895911 Plasmodium falciparum (isolate Camp / Malaysia) Erythrocyte-binding antigen 175 Proteins 0.000 description 1
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
- 101710203837 Replication-associated protein Proteins 0.000 description 1
- 101150078331 ama-1 gene Proteins 0.000 description 1
- 101150089906 resA gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims >' 1. An antigen based vaccine against malaria comprising a fusion protein derived from Plasmodium falciparum Glutamate-rich protein (GLURP) genetically coupled to at least one other Plasmodium falciparum derived protein or a homologue of said fusion protein. 2. An antigen based vaccine against malaria according to claim 1 where the protein genetically coupled to GLURP is derived from the Merozoite surface protein 3 (MSP3) from Plasmodium falciparum. 3. A vaccine according to claim 2 comprising SEQ ID NO 1 4. A vaccine according to claim 2 or 3 further comprising an immunogenic fragment of a protein derived from Plasmodium falciparum 5. A fusion protein comprising SEQ ID NO. 1 or a homologue hereof. 6. A fusion protein according to claim 5 further comprising one or more immunogenic fragments of one or more proteins derived from Plasmodium falciparum. 7. A fusion protein according to claim 6 where the immunogenic fragment is chosen from CS, MSP1, MSP2, MSP4, MAP5, MSP6, AMA1, Pf155/RESA, RAP1, EBA-175, ΕΜΡΙ,ΕΧΡΙ, LSA1, LSA3, Pf25, Pf45/48, ΡΓ230, Pf27, Pfl6, or Pf28. 8. Preparation of a fusion protein according to claim 5-7 from a recombinant
Lactococcus sp. 9. A nucleic acid comprising SEQ ID NO. 2 or a homologue hereof. 10. A nucleic acid coding for a fusion protein according to claim 6 or 7 11. Use of a nucleic acid according to claim 9 or 10 for the preparation of a vaccine. A vaccine comprising a recombinant BCG expressing the nucleic acid sequence according to claim 9 or 10.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200201741A DK200201741A (da) | 2002-11-12 | 2002-11-12 | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| DK03810941T DK1567189T3 (da) | 2002-11-12 | 2003-11-06 | Malariavaccine |
| PCT/DK2003/000759 WO2004043488A1 (en) | 2002-11-12 | 2003-11-06 | Malaria vaccine |
| BR0315205-7A BR0315205A (pt) | 2002-11-12 | 2003-11-06 | Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo |
| HK06102595.9A HK1080754B (en) | 2002-11-12 | 2003-11-06 | Malaria vaccine |
| AT03810941T ATE432081T1 (de) | 2002-11-12 | 2003-11-06 | Malaria-vakzine |
| EP03810941A EP1567189B1 (en) | 2002-11-12 | 2003-11-06 | Malaria vaccine |
| ES03810941T ES2326415T3 (es) | 2002-11-12 | 2003-11-06 | Vacuna contra la malaria. |
| JP2005506641A JP4573773B2 (ja) | 2002-11-12 | 2003-11-06 | マラリア・ワクチン |
| DE60327801T DE60327801D1 (de) | 2002-11-12 | 2003-11-06 | Malaria-vakzine |
| AU2003275949A AU2003275949B2 (en) | 2002-11-12 | 2003-11-06 | Malaria vaccine |
| CN2003801031543A CN1741815B (zh) | 2002-11-12 | 2003-11-06 | 疟疾疫苗 |
| CA2505724A CA2505724C (en) | 2002-11-12 | 2003-11-06 | Malaria vaccine |
| US11/128,660 US7749507B2 (en) | 2002-11-12 | 2005-05-12 | Malaria vaccine |
| ZA200504415A ZA200504415B (en) | 2002-11-12 | 2006-01-17 | Malaria vaccine |
| US12/793,575 US20110020387A1 (en) | 2002-11-12 | 2010-06-03 | Malaria vaccine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200201741A DK200201741A (da) | 2002-11-12 | 2002-11-12 | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| DKPA200301307 | 2003-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200201741A true DK200201741A (da) | 2003-09-16 |
Family
ID=32313776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200201741A DK200201741A (da) | 2002-11-12 | 2002-11-12 | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| DK03810941T DK1567189T3 (da) | 2002-11-12 | 2003-11-06 | Malariavaccine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03810941T DK1567189T3 (da) | 2002-11-12 | 2003-11-06 | Malariavaccine |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7749507B2 (da) |
| EP (1) | EP1567189B1 (da) |
| JP (1) | JP4573773B2 (da) |
| CN (1) | CN1741815B (da) |
| AT (1) | ATE432081T1 (da) |
| AU (1) | AU2003275949B2 (da) |
| BR (1) | BR0315205A (da) |
| CA (1) | CA2505724C (da) |
| DE (1) | DE60327801D1 (da) |
| DK (2) | DK200201741A (da) |
| ES (1) | ES2326415T3 (da) |
| WO (1) | WO2004043488A1 (da) |
| ZA (1) | ZA200504415B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161840A1 (en) * | 1992-10-19 | 2003-08-28 | Institut Pasteur | Plasmodium falciparum antigens inducing protective antibodies |
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| US20050112133A1 (en) * | 2003-10-24 | 2005-05-26 | Pierre Druilhe | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it |
| US7488489B2 (en) | 2004-08-03 | 2009-02-10 | Institut Pasteur | Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies |
| KR101616572B1 (ko) * | 2009-05-05 | 2016-05-11 | 카딜라 핼쓰캐어 리미티드 | 홍역-말라리아 조합 백신 |
| CN102471361B (zh) | 2009-07-15 | 2016-06-01 | 不列颠哥伦比亚大学 | 作为神经氨酸酶抑制剂的2,3-氟化糖苷及其作为抗病毒药物的用途 |
| EP2385107B1 (en) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
| DK2763694T3 (da) | 2011-10-04 | 2018-04-16 | Statens Seruminstitut | Fremstilling af et cystein-rigt protein |
| WO2013082394A1 (en) * | 2011-11-30 | 2013-06-06 | The Regents Of The University Of California | Immunogenic plasmodium falciparum antigen compositions and uses thereof |
| CN102533677B (zh) * | 2012-01-10 | 2013-07-24 | 特菲(天津)生物医药科技有限公司 | 一种疟疾疫苗及其制备方法 |
| CN107954963A (zh) | 2012-01-19 | 2018-04-24 | 不列颠哥伦比亚大学 | 3’平伏氟取代的神经氨酸酶抑制剂化合物、组合物及其用作抗病毒剂的方法 |
| CN105628928A (zh) * | 2014-11-11 | 2016-06-01 | 深圳国际旅行卫生保健中心 | 可用于辅助诊断疟疾的试剂盒 |
| CN105652009B (zh) * | 2014-11-11 | 2018-04-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | 可用于辅助诊断疟疾的试剂盒 |
| KR20190044587A (ko) | 2016-05-19 | 2019-04-30 | 아메드 에스.아이. 앨리 | 합성 말라리아 면역원, 이의 조합, 및 말라리아 감염을 예방하고 치료하기 위한 이의 용도 |
| BR112019001115A2 (pt) * | 2016-07-21 | 2019-06-25 | Vac4All Pte Ltd | proteínas de biofusão como vacinas anti-malária |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002811A1 (en) * | 1988-09-16 | 1990-03-22 | Statens Seruminstitut | A malaria antigen |
| DK519188D0 (da) * | 1988-09-16 | 1988-09-16 | Statens Seruminstitut | Kemisk forbindelse |
| US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| AU3158900A (en) * | 1999-02-25 | 2000-09-14 | Smithkline Beecham Biologicals (Sa) | Immunogens comprising a peptide and a carrier derived from h.influenzae protein |
| WO2002092628A2 (fr) * | 2001-05-16 | 2002-11-21 | Institut Pasteur | Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
-
2002
- 2002-11-12 DK DK200201741A patent/DK200201741A/da not_active Application Discontinuation
-
2003
- 2003-11-06 AU AU2003275949A patent/AU2003275949B2/en not_active Expired
- 2003-11-06 DE DE60327801T patent/DE60327801D1/de not_active Expired - Lifetime
- 2003-11-06 AT AT03810941T patent/ATE432081T1/de not_active IP Right Cessation
- 2003-11-06 JP JP2005506641A patent/JP4573773B2/ja not_active Expired - Fee Related
- 2003-11-06 WO PCT/DK2003/000759 patent/WO2004043488A1/en not_active Ceased
- 2003-11-06 ES ES03810941T patent/ES2326415T3/es not_active Expired - Lifetime
- 2003-11-06 DK DK03810941T patent/DK1567189T3/da active
- 2003-11-06 CA CA2505724A patent/CA2505724C/en not_active Expired - Lifetime
- 2003-11-06 EP EP03810941A patent/EP1567189B1/en not_active Expired - Lifetime
- 2003-11-06 CN CN2003801031543A patent/CN1741815B/zh not_active Expired - Lifetime
- 2003-11-06 BR BR0315205-7A patent/BR0315205A/pt not_active IP Right Cessation
-
2005
- 2005-05-12 US US11/128,660 patent/US7749507B2/en not_active Expired - Lifetime
-
2006
- 2006-01-17 ZA ZA200504415A patent/ZA200504415B/en unknown
-
2010
- 2010-06-03 US US12/793,575 patent/US20110020387A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2326415T3 (es) | 2009-10-09 |
| JP4573773B2 (ja) | 2010-11-04 |
| EP1567189A1 (en) | 2005-08-31 |
| US20110020387A1 (en) | 2011-01-27 |
| US7749507B2 (en) | 2010-07-06 |
| HK1080754A1 (en) | 2006-05-04 |
| ATE432081T1 (de) | 2009-06-15 |
| ZA200504415B (en) | 2006-03-29 |
| CA2505724C (en) | 2015-06-30 |
| US20060024324A1 (en) | 2006-02-02 |
| AU2003275949B2 (en) | 2008-06-05 |
| CA2505724A1 (en) | 2004-05-27 |
| EP1567189B1 (en) | 2009-05-27 |
| CN1741815A (zh) | 2006-03-01 |
| WO2004043488A1 (en) | 2004-05-27 |
| JP2006512926A (ja) | 2006-04-20 |
| DK1567189T3 (da) | 2009-09-14 |
| CN1741815B (zh) | 2010-05-26 |
| DE60327801D1 (de) | 2009-07-09 |
| BR0315205A (pt) | 2005-08-16 |
| AU2003275949A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Acquah et al. | Transmission-blocking vaccines: old friends and new prospects | |
| Mahanty et al. | Progress in the development of recombinant and synthetic blood-stage malaria vaccines | |
| Moelans et al. | A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites | |
| Eichinger et al. | Circumsporozoite protein of Plasmodium berghei: gene cloning and identification of the immunodominant epitopes | |
| Fidock et al. | Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP | |
| Sinnis et al. | Cell invasion by the vertebrate stages of Plasmodium | |
| Lobo et al. | Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies | |
| Ramasamy | Molecular basis for evasion of host immunity and pathogenesis in malaria | |
| FR2744724B1 (fr) | Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques | |
| Webster et al. | Progress with new malaria vaccines | |
| US20110020387A1 (en) | Malaria vaccine | |
| JP2006512926A5 (da) | ||
| Yoshida et al. | Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite | |
| WO2003016354A3 (en) | Recombinant anti-plasmodium falciparum antibodies | |
| Gardner et al. | DNA vaccines against malaria: immunogenicity and protection in a rodent model | |
| RU2007109608A (ru) | Вакцины, содержащие антиген plasmodium | |
| Kaslow et al. | Malaria transmission-blocking vaccines | |
| Patarroyo et al. | Functionally relevant proteins in Plasmodium falciparum host cell invasion | |
| EP0584201B1 (en) | Transmission-blocking vaccine against malaria | |
| IL90134A0 (en) | Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions | |
| Zhang et al. | Construction and evaluation of a multistage combination vaccine against malaria | |
| DE60235044D1 (de) | REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN | |
| CN100457780C (zh) | 重组恶性疟原虫175kD红细胞结合抗原功能区蛋白及其制法和用途 | |
| Targett | Status of malaria vaccine research | |
| Sauerwein et al. | Sexual and sporogonic stage antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |